Date | December 27, 2020 – present |
---|---|
Duration | 3 years, 4 months and 19 days |
Location | Spain |
Cause | COVID-19 pandemic in Spain |
Target | Adult population (age 12+) and children (age 5+) |
Organised by | Ministry of Health |
Participants | 40.911.451 people |
Outcome | 86,2% partially vaccinated (1 of 2 doses) 80,7% fully vaccinated [1] (46,2% with booster dose) |
Website | Gobierno de España |
Updated in January 31, 2022 |
The COVID-19 vaccination in Spain is the national vaccination strategy started on 27 December 2020 in order to vaccinate the country's population against COVID-19 within the international effort to fight the COVID-19 pandemic.
As of November 23, 2021, the following doses had been received: 59,296,575 Pfizer–BioNTech COVID-19 vaccine doses, 16,105,300 Moderna vaccine doses, 17,427,500 Oxford–AstraZeneca vaccine doses and 2,659,000 Janssen vaccine doses, totaling to 95,488,375 doses. Out of these doses, 75,173,640 had been administered.
The autonomous communities with the highest fully-vaccinated percentage are Asturias (85.1%) and Galicia (84.9%), while the communities with the lowest percentage are the Canary Islands (75.7%) and the Balearic Islands (72.4%). The Spanish average percentage was 79.1%, amounting to 37,557,243 people.
Out of the total, 3,776,118 have been administered as additional doses, or third doses, of which 3,319,229 are Pfizer–BioNTech COVID-19 vaccine doses and 456,889 are Moderna vaccine doses.
The amount of doses ordered from Q1 to Q4 of 2021 is 141,943,261.
There are several COVID-19 vaccines at various stages of development around the world.
Vaccine | Doses ordered | Approval | Deployment | Age Applied [2] |
---|---|---|---|---|
Pfizer–BioNTech | 146 million | 21 December 2020 | 27 December 2020 | 12+ |
Moderna | 52 million | 6 January 2021 | 12 January 2021 | 12+ |
Oxford-AstraZeneca | 31 million | 29 January 2021 | 7 February 2021 | 60–69 |
Janssen | 20 million | 11 March 2021 | 5 May 2021 | 40+ |
Novavax | 2,2 million | 20 December 2021 | Pending | Pending |
Valneva | Pending | Pending | Pending | Pending |
Sanofi–GSK | Pending | Pending | Pending | Pending |
CureVac | Request withdrawn | Request withdrawn | No | No |
According to the Government of Spain, the vaccination campaign, which is being carried out voluntarily, is structured in four phases. These phases are at the same time formed by different population groups defined in the National COVID-19 Vaccination Strategy : [3]
Phases | Population group | Development [lower-alpha 1] | ||
---|---|---|---|---|
1st doses | 2nd doses [lower-alpha 2] | |||
0 | Development, approval and assessment. | |||
1 | Priority groups | Elderly and disabled care homes' residents and staff | Completed (99,3%) [lower-alpha 3] | Completed (92,0%) [lower-alpha 3] |
First line health and socio-sanitary professionals | Completed | Completed | ||
Other health and socio-sanitary professionals | Completed | Completed | ||
Highly dependent people not living in care homes | Completed | Completed | ||
2 (In progress) | Other priority groups | All those aged 80 and older | >100,0% [lower-alpha 4] | >100,0% [lower-alpha 4] |
All those aged between 70 and 79 and those with very high risk conditions | 99,1% [lower-alpha 5] | 98,2% [lower-alpha 5] | ||
All those aged between 60 and 69 | 97,9% | 95,1% | ||
Other health and socio-sanitary professionals | Completed | Completed | ||
Workers with an essential social role | Completed | Completed | ||
All those aged between 50 and 59 | 97,4% | 93,1% | ||
3 (In progress) | Rest of priority groups | All those aged between 40 and 49 | 88,9% | 85,6% |
All those aged between 30 and 39 | 74,4% | 72,7% | ||
All those aged between 20 and 29 | 73,0% | 70,0% | ||
All those aged between 12 and 19 | 80,7% | 77,2% | ||
TOTALS | ||||
Current prioritary goal (all those aged 40 and over) | 94,2% | 92,1% | ||
Target population (all those aged 12 and over) | 90,8% | 85,5% | ||
Spanish total population | 79,5% | 77,3% |
Notes: The information shown in the table is collected up to September 1, 2021.
According to the Centre for Sociological Research, the Spanish public organism in charge of investigating the public opinion of the society on many different topics, these are the data of the acceptance of the vaccine among the Spanish population:
Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | ||
---|---|---|---|---|---|---|---|---|---|---|
YES | Yes | 40,2% | 36,8% | 40,5% | 72,5% | 82,9% | 82,5% | 70,4% | 53,2% | 37,8% |
They are already vaccinated | – | – | – | – | – | 5,1% | 15,0% | 37,7% | 55,1% | |
Yes, depending on the origin of the vaccine | 0,2% | 0,1% | 0,6% | 0,2% | 0,4% | 0,6% | 2,4% | 1,2% | 0,4% | |
Yes, if there are guarantees, if it is proven, if it is reliable | 2,2% | 1,4% | 16,2% | 2,5% | 1,8% | 0,9% | 1,6% | 0,5% | 0,2% | |
Yes, on the advice of the authorities, scientists or health professionals | 0,2% | 0,3% | 3,6% | 1,3% | 0,9% | 0,3% | 0,4% | 0,3% | 0,1% | |
Yes, if there is enough information | 0,2% | 0,0% | 3,2% | 0,8% | 0,4% | 0,2% | 0,3% | 0,2% | 0,1% | |
TOTAL YES | 43,0% | 38,6% | 64,1% | 77,3% | 86,4% | 89,6% | 90,1% | 93,1% | 93,7% | |
NO | No | 43,8% | 47,0% | 28,0% | 16,5% | 6,5% | 5,4% | 5,3% | 3,7% | 3,6% |
TOTAL NO | 43,8% | 47,0% | 28,0% | 16,5% | 6,5% | 5,4% | 5,3% | 3,7% | 3,6% | |
NK + NA | Does not know, doubts | 12,4% | 13,4% | 5,3% | 4,5% | 5,5% | 3,8% | 3,3% | 2,4% | 1,8% |
Other answers | 0,6% | 0,7% | 2,5% | 1,7% | 1,6% | 1,0% | 1,3% | 0,7% | 0,6% | |
N.A. (Not answers) | 0,4% | 0,3% | 0,1% | 0,1% | 0,1% | 0,0% | 0,1% | 0,0% | 0,1% | |
TOTAL NK/NA (OTHER ANSWERS) | 13,4% | 14,4% | 7,9% | 6,3% | 7,2% | 4,8% | 4,7% | 3,1% | 2,5% | |
Sample | 2.924 | 3.853 | 3.817 | 3.852 | 3.869 | 3.820 | 3.823 | 3.814 | 3.814 | |
Reference | [5] | [6] | [7] | [8] | [9] | [10] | [11] | [12] | [13] |
From February 2021 onwards, the centre began to ask among those who did not want to take the vaccine about the reasons they had for choosing not to receive the shot, obtaining the following results:
February 2021 | March 2021 | April 2021 | May 2021 | June 2021 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
% question | % total sample | % question | % total sample | % question | % total sample | % question | % total sample | % question | % total sample | |
They do not rely on these vaccines | 31,2% | 2,0280% | 29,3% | 1,5822% | 34,6% | 1,8338% | 25,3% | 0,9361% | 35,4% | 1,2744% |
Because of fear to develop risks for their health/side-collateral effects | 18,5% | 1,2025% | 20,1% | 1,0854% | 25,3% | 1,3409% | 25,3% | 0,9361% | 15,6% | 0,5616% |
They are against all vaccines in general | 4,3% | 0,2795% | 1,7% | 0,0981% | 3,1% | 0,1643% | 4,4% | 0,1628% | 7,1% | 0,2556% |
They prefer to wait to see how they work | 9,2% | 0,5980% | 6,0% | 0,3240% | 3,5% | 0,1855% | 7,7% | 0,2849% | 6,9% | 0,2484% |
They do not believe they are effective | 8,3% | 0,5395% | 7,1% | 0,3834% | 5,2% | 0,2756% | 8,7% | 0,3219% | 5,2% | 0,1872% |
They do not consider it necessary (without specifying) | – | – | 4,6% | 0,2484% | 3,7% | 0,1961% | 7,3% | 0,2701% | 4,7% | 0,1692% |
Because of lack of guarantees: few trials, earliness, lack of analysis | 4,6% | 0,2990% | 4,6% | 0,2484% | 3,7% | 0,1961% | 4,2% | 0,1554% | 3,1% | 0,1116% |
COVID-19 denial | – | – | 3,1% | 0,1674% | 2,8% | 0,1484% | 0,7% | 0,0259% | 3,1% | 0,1116% |
Because of having few possibilities of infection | 3,2% | 0,2080% | 3,5% | 0,1890% | 1,0% | 0,0530% | 4,8% | 0,1776% | 3,0% | 0,1080% |
Because of having allergies, other diseases or treatments, breastfeeding, pregnancy | 3,0% | 0,1950% | 2,1% | 0,1134% | 3,6% | 0,1908% | 3,7% | 0,1369% | 2,3% | 0,0828% |
Because of having passed COVID-19 | – | – | 4,6% | 0,2484% | 3,4% | 0,1802% | 0,2% | 0,0074% | 2,2% | 0,0792% |
Because of lack of information | 1,5% | 0,0975% | 3,7% | 0,1998% | 1,1% | 0,0583% | 0,7% | 0,0259% | 1,4% | 0,0504% |
There are other people more vulnerable or with a higher risk than them | 0,8% | 0,052% | 1,0% | 0,0540% | – | – | – | – | 0,8% | 0,0288% |
They do not ever get vaccinated | 1,0% | 0,0650% | 1,5% | 0,0810% | 1,6% | 0,0848% | 1,5% | 0,0555% | - | - |
Because of any other reason | 12,9% | 0,8385% | 4,9% | 0,2646% | 5,8% | 0,3074% | 3,1% | 0,1147% | 7,3% | 0,2628% |
They do not know, doubt | 1,3% | 0,0845% | 1,9% | 0,1026% | 1,0% | 0,0530% | 1,8% | 0,0666% | - | - |
N.A. (Not answers) | 0,2% | 0,0130% | – | – | 0,5% | 0,0265% | 0,8% | 0,0296% | 1,9% | 0,0684% |
Sample | 251 | 3.869 | 208 | 3.820 | 203 | 3.823 | 143 | 3.814 | 138 | 3.814 |
Reference | [9] | [10] | [11] | [12] | [13] |
The progress of the vaccination campaign to more and more demographic groups has allowed many public figures to receive one or two doses of the vaccine correspondent to them by age or belonging to some other priority group.
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
The Therapeutic Goods Administration (TGA) is the medicine and therapeutic regulatory agency of the Australian Government. As part of the Department of Health and Aged Care, the TGA regulates the quality, supply and advertising of medicines, pathology devices, medical devices, blood products and most other therapeutics. Any items that claim to have a therapeutic effect, are involved in the administration of medication, or are otherwise covered by the Therapeutic Goods Act 1989, the Therapeutic Goods Regulations 1990, or a ministerial order, must be approved by the TGA and registered in the Australian Register of Therapeutic Goods.
The COVID-19 vaccination program in the Philippines was a mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the pandemic in the country. The vaccination program was initiated by the Duterte administration on March 1, 2021, a day after the arrival of the country's first vaccine doses which were donated by the Chinese government.
Vaccination against COVID-19 in Sweden started on 27 December 2020 after the approval of the Pfizer–BioNTech vaccine by the European Commission. In Sweden, the Public Health Agency has been commissioned by the government to create a vaccination plan. Sveriges riksbank, the central bank of Sweden, predicts that efficient vaccination against COVID-19 has macroeconomic benefits. As of 20 April 2022, 87.1% of people in Sweden have received at least one dose, with a total of 21,491,717 doses administered.: At least one vaccine has been approved for all age groups 12 and older. Children younger than 12 in high risk groups can also be vaccinated.
The COVID-19 vaccination campaign in Italy is a mass immunization campaign that was put in place by the Italian government in order to respond to the ongoing COVID-19 pandemic. It started on 27 December 2020, together with most countries in the European Union.
Israel's COVID-19 vaccination programme, officially named "Give a Shoulder", began on 19 December 2020, and has been praised for its speed, having given twenty percent of the Israeli population the first dose of the vaccines' two dose regimen in the span of three weeks.
The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, with the goal of vaccinating all willing people in Australia before 2022. Front-line workers and aged care staff and residents had priority for being inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine was not included in the Australian vaccination program as of June 2021.
The COVID-19 vaccination programme in the Republic of Ireland is an ongoing mass immunisation campaign that began on 29 December 2020 in response to the COVID-19 pandemic in the Republic of Ireland. Ireland's vaccination rollout has been praised as one of the most successful rollouts in the world and was ranked number one in the European Union in terms of its percentage of adult population fully vaccinated, and was also ranked number one in the EU for the number of booster vaccines administered.
COVID-19 vaccination in Canada is an ongoing, intergovernmental effort coordinated between the bodies responsible in the Government of Canada to acquire and distribute vaccines to individual provincial and territorial governments who in turn administer authorized COVID-19 vaccines during the COVID-19 pandemic in Canada. Provinces have worked with local municipal governments, hospital systems, family doctors and independently owned pharmacies to aid in part, or in full with vaccination rollout. The vaccination effort in full is the largest such immunization effort in the nation's history. The vaccination effort began December 14, 2020, and is currently ongoing.
COVID-19 vaccination in South Africa is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination program in Colombia is an ongoing effort of mass immunization put in place by the Colombian government in order to respond to the ongoing COVID-19 pandemic. The virus causing COVID-19 was confirmed to have reached Colombia on 6 March 2020. Colombia's preparation and readiness for a vaccine program allowed it to join the first group of countries who received vaccines through COVAX. The first vaccine in Colombia was given to a nurse on 17 February 2021.
COVID-19 vaccination programs are ongoing in the majority countries and territories in Africa, with 51 of 54 African countries having launched vaccination programs by July 2021. As of October 2023, 51.8% of the continent's population is fully vaccinated with over 1084.5 million doses administered.
COVID-19 vaccination in Mexico is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination campaign in Quebec is an ongoing provincial effort to distribute and administer vaccines against COVID-19.
The COVID-19 vaccination program in Argentina is an ongoing effort of mass immunization. Vaccination against COVID-19 began in Argentina on 29 December 2020 aiming at health professionals. Argentina struck a deal with the United Kingdom in November 2020 for a British made vaccine produced by the pharmaceutical company AstraZeneca and the University of Oxford. The vaccines are part of a deal where Argentina received 22.4 million doses. During the first week, 39,599 doses were applied to health professionals.
The COVID-19 vaccination in Singapore is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Singapore has a very high vaccination rate, with more than 92% of its total population having completed their vaccination regimen.
The COVID-19 vaccination campaign in Brazil is an ongoing mass immunization campaign for the COVID-19 pandemic in Brazil. It started on January 17, 2021, when the country had 210 thousand deaths.
The COVID-19 vaccination campaign in Ukraine is an ongoing mass immunization campaign for the COVID-19 pandemic in Ukraine.
COVID-19 vaccination in Ontario began in December 2020, when the first doses of the Pfizer vaccine were administered. In February 2021, shipments for both the Pfizer and Moderna vaccines increased significantly. By May 2021, over 50 percent of Ontarians had received their first dose. By the beginning of 2022, over 80 percent of Ontarians had received their first dose.